| Item Type | Name |
|
Academic Article
|
Levels of soluble cell adhesion molecules in patients with dyslipidemia.
|
|
Academic Article
|
The Lipoprotein and Coronary Atherosclerosis Study (LCAS): design, methods, and baseline data of a trial of fluvastatin in patients without severe hypercholesterolemia.
|
|
Academic Article
|
Risk for myopathy with statin therapy in high-risk patients.
|
|
Academic Article
|
Reducing atherothrombotic events in high-risk patients: recent data on therapy with statins and fatty acids.
|
|
Academic Article
|
Possible differences between fibrates in pharmacokinetic interactions with statins.
|
|
Academic Article
|
Fluvastatin reduces cardiac mortality in patients with coronary heart disease.
|
|
Academic Article
|
Statin use and risks of death or fatal rejection in the Heart Transplant Lipid Registry.
|
|
Academic Article
|
Efficacy of rosuvastatin 10 mg in patients with the metabolic syndrome.
|
|
Academic Article
|
Combination therapy for combined dyslipidemia.
|
|
Academic Article
|
Does preoperative statin therapy improve outcomes in patients undergoing isolated cardiac valve surgery?
|
|
Academic Article
|
Efficacy and safety of rosuvastatin alone and in combination with cholestyramine in patients with severe hypercholesterolemia: a randomized, open-label, multicenter trial.
|
|
Academic Article
|
Pooled analyses of effects on C-reactive protein and low density lipoprotein cholesterol in placebo-controlled trials of ezetimibe monotherapy or ezetimibe added to baseline statin therapy.
|
|
Academic Article
|
Effect of niacin ER/lovastatin on claudication symptoms in patients with peripheral artery disease.
|
|
Academic Article
|
Carotid atherosclerosis progression in familial hypercholesterolemia patients: a pooled analysis of the ASAP, ENHANCE, RADIANCE 1, and CAPTIVATE studies.
|
|
Academic Article
|
A comparative study with rosuvastatin in subjects with metabolic syndrome: results of the COMETS study.
|
|
Academic Article
|
Relationship between circulating levels of RANTES (regulated on activation, normal T-cell expressed, and secreted) and carotid plaque characteristics: the Atherosclerosis Risk in Communities (ARIC) Carotid MRI Study.
|
|
Academic Article
|
Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE] trial).
|
|
Academic Article
|
Barriers to non-HDL cholesterol goal attainment by providers.
|
|
Academic Article
|
Authors' reply.
|
|
Academic Article
|
Preoperative statin therapy is not associated with a decrease in the incidence of postoperative atrial fibrillation in patients undergoing cardiac surgery.
|
|
Academic Article
|
The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study.
|
|
Academic Article
|
Low-density lipoprotein cholesterol reduction and goal achievement with ezetimibe/simvastatin versus atorvastatin or rosuvastatin in patients with diabetes, metabolic syndrome, or neither disease, stratified by National Cholesterol Education Program risk category.
|
|
Academic Article
|
Preoperative statin therapy decreases risk of postoperative renal insufficiency.
|
|
Academic Article
|
Variability and persistence of aspirin response in lower extremity peripheral arterial disease patients.
|
|
Academic Article
|
Pharmacological strategies for lowering LDL cholesterol: statins and beyond.
|
|
Academic Article
|
The editor's roundtable: JUPITER follow-up.
|
|
Academic Article
|
Effect of two intensive statin regimens on progression of coronary disease.
|
|
Academic Article
|
Efficacy and safety of a novel oral inducer of apolipoprotein a-I synthesis in statin-treated patients with stable coronary artery disease a randomized controlled trial.
|
|
Academic Article
|
Long-term efficacy of adding fenofibric acid to moderate-dose statin therapy in patients with persistent elevated triglycerides.
|
|
Academic Article
|
Association between statins and infections after coronary artery bypass grafting.
|
|
Academic Article
|
Alteration of relation of atherogenic lipoprotein cholesterol to apolipoprotein B by intensive statin therapy in patients with acute coronary syndrome (from the Limiting UNdertreatment of lipids in ACS With Rosuvastatin [LUNAR] Trial).
|
|
Academic Article
|
Lifestyle intervention and/or statins for the reduction of C-reactive protein in type 2 diabetes: from the look AHEAD study.
|
|
Academic Article
|
Maximizing the cost-effectiveness of lipid-lowering therapy.
|
|
Academic Article
|
Interactions between angiotensin-I converting enzyme insertion/deletion polymorphism and response of plasma lipids and coronary atherosclerosis to treatment with fluvastatin: the lipoprotein and coronary atherosclerosis study.
|
|
Academic Article
|
Statins and inflammatory markers.
|
|
Academic Article
|
Efficacy and safety of ezetimibe coadministered with statins: randomised, placebo-controlled, blinded experience in 2382 patients with primary hypercholesterolemia.
|
|
Academic Article
|
Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial.
|
|
Academic Article
|
Achieving LDL cholesterol, non-HDL cholesterol, and apolipoprotein B target levels in high-risk patients: Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapY (MERCURY) II.
|
|
Academic Article
|
Lipid-altering efficacy of the ezetimibe/simvastatin single tablet versus rosuvastatin in hypercholesterolemic patients.
|
|
Academic Article
|
Efficacy and safety of rosuvastatin 40 mg alone or in combination with ezetimibe in patients at high risk of cardiovascular disease (results from the EXPLORER study).
|
|
Academic Article
|
Meta-analysis of the cholesterol-lowering effect of ezetimibe added to ongoing statin therapy.
|
|
Academic Article
|
Long-term efficacy and safety of rosuvastatin 40 mg in patients with severe hypercholesterolemia.
|
|
Academic Article
|
Efficacy and tolerability of fluvastatin XL 80 mg alone, ezetimibe alone, and the combination of fluvastatin XL 80 mg with ezetimibe in patients with a history of muscle-related side effects with other statins.
|
|
Academic Article
|
Statin therapy alters the relationship between apolipoprotein B and low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol targets in high-risk patients: the MERCURY II (Measuring Effective Reductions in Cholesterol Using Rosuvastatin) trial.
|
|
Academic Article
|
Variants in the APOA5 gene region and the response to combination therapy with statins and fenofibric acid in a randomized clinical trial of individuals with mixed dyslipidemia.
|
|
Academic Article
|
Clinical utility of inflammatory markers and advanced lipoprotein testing: advice from an expert panel of lipid specialists.
|
|
Academic Article
|
Effects of combination therapy with rosuvastatin and fenofibric acid in patients with mixed dyslipidemia and high-sensitivity C-reactive protein (= 2 mg/L). cmb@bcm.tmc.edu.
|
|
Academic Article
|
LPL gene variants affect apoC-III response to combination therapy of statins and fenofibric acid in a randomized clinical trial of individuals with mixed dyslipidemia.
|
|
Concept
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors
|
|
Academic Article
|
Factors underlying regression of coronary atheroma with potent statin therapy.
|
|
Academic Article
|
Coronary atheroma volume and cardiovascular events during maximally intensive statin therapy.
|
|
Academic Article
|
C-reactive protein, but not low-density lipoprotein cholesterol levels, associate with coronary atheroma regression and cardiovascular events after maximally intensive statin therapy.
|
|
Academic Article
|
Efficacy, safety and effect on biomarkers related to cholesterol and lipoprotein metabolism of rosuvastatin 10 or 20 mg plus ezetimibe 10 mg vs. simvastatin 40 or 80 mg plus ezetimibe 10 mg in high-risk patients: Results of the GRAVITY randomized study.
|
|
Academic Article
|
Long-term effects of maximally intensive statin therapy on changes in coronary atheroma composition: insights from SATURN.
|
|
Academic Article
|
The ACC/AHA 2013 guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: the good the bad and the uncertain: a comparison with ESC/EAS guidelines for the management of dyslipidaemias 2011.
|
|
Academic Article
|
A 52-week placebo-controlled trial of evolocumab in hyperlipidemia.
|
|
Academic Article
|
Rare LPL gene variants attenuate triglyceride reduction and HDL cholesterol increase in response to fenofibric acid therapy in individuals with mixed dyslipidemia.
|
|
Academic Article
|
Effects of fenofibric acid on carotid intima-media thickness in patients with mixed dyslipidemia on atorvastatin therapy: randomized, placebo-controlled study (FIRST).
|
|
Academic Article
|
Effects of icosapent ethyl on lipid and inflammatory parameters in patients with diabetes mellitus-2, residual elevated triglycerides (200-500 mg/dL), and on statin therapy at LDL-C goal: the ANCHOR study.
|
|
Academic Article
|
High-intensity statin therapy alters the natural history of diabetic coronary atherosclerosis: insights from SATURN.
|
|
Academic Article
|
Is high-intensity statin therapy associated with lower statin adherence compared with low- to moderate-intensity statin therapy? Implications of the 2013 American College of Cardiology/American Heart Association Cholesterol Management Guidelines.
|
|
Academic Article
|
Pharmacogenetic meta-analysis of genome-wide association studies of LDL cholesterol response to statins.
|
|
Academic Article
|
Eligibility for statin therapy according to new cholesterol guidelines and prevalent use of medication to lower lipid levels in an older US Cohort: the Atherosclerosis Risk in Communities Study Cohort.
|
|
Academic Article
|
Gender disparities in evidence-based statin therapy in patients with cardiovascular disease.
|
|
Academic Article
|
Statins, plasma cholesterol, and risk of Parkinson's disease: a prospective study.
|
|
Academic Article
|
Efficacy and safety of evolocumab in reducing lipids and cardiovascular events.
|
|
Academic Article
|
Results of bococizumab, a monoclonal antibody against proprotein convertase subtilisin/kexin type 9, from a randomized, placebo-controlled, dose-ranging study in statin-treated subjects with hypercholesterolemia.
|
|
Academic Article
|
The effect of BMS-582949, a P38 mitogen-activated protein kinase (P38 MAPK) inhibitor on arterial inflammation: a multicenter FDG-PET trial.
|
|
Academic Article
|
Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester): Effects Upon High-Sensitivity C-Reactive Protein and Lipid Parameters in Patients With Metabolic Syndrome.
|
|
Academic Article
|
Implications for Ezetimibe Therapy Use Based on IMPROVE-IT Criteria.
|
|
Academic Article
|
Effects of icosapent ethyl on lipoprotein particle concentration and size in statin-treated patients with persistent high triglycerides (the ANCHOR Study).
|
|
Academic Article
|
Validity of self-report of lipid medication use: the Atherosclerosis Risk in Communities (ARIC) Study.
|
|
Academic Article
|
Case-based educational intervention to assess change in providers' knowledge and attitudes towards the 2013 American College of Cardiology/American Heart Association Cholesterol Management Guideline.
|
|
Academic Article
|
Comparison of PCSK9 Inhibitor Evolocumab vs Ezetimibe in Statin-Intolerant Patients: Design of the Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin-Intolerant Subjects 3 (GAUSS-3) Trial.
|
|
Academic Article
|
Treatment Gaps in Adults With Heterozygous Familial Hypercholesterolemia in the United States: Data From the CASCADE-FH Registry.
|
|
Academic Article
|
Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance: The GAUSS-3 Randomized Clinical Trial.
|
|
Academic Article
|
2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents.
|
|
Academic Article
|
Statin Use and Its Facility-Level Variation in Patients With Diabetes: Insight From the Veterans Affairs National Database.
|
|
Academic Article
|
Effect of ETC-1002 on Serum Low-Density Lipoprotein Cholesterol in Hypercholesterolemic Patients Receiving Statin Therapy.
|
|
Academic Article
|
Accuracy of the Atherosclerotic Cardiovascular Risk Equation in?a?Large?Contemporary, Multiethnic?Population.
|
|
Academic Article
|
Treatment with ETC-1002 alone and in combination with ezetimibe lowers LDL cholesterol in hypercholesterolemic patients with or without statin intolerance.
|
|
Academic Article
|
Practice-Level Variation in?Statin Use Among Patients With Diabetes: Insights From the PINNACLE Registry.
|
|
Academic Article
|
Risk Factor Optimization and Guideline-Directed Medical Therapy in US Veterans With Peripheral Arterial and Ischemic Cerebrovascular Disease Compared to Veterans With Coronary Heart Disease.
|
|
Academic Article
|
Icosapent ethyl (eicosapentaenoic acid ethyl ester): Effects on remnant-like particle cholesterol from the MARINE and ANCHOR studies.
|
|
Academic Article
|
Meta-analysis of genome-wide association studies of HDL cholesterol response to statins.
|
|
Academic Article
|
Bempedoic Acid (ETC-1002): an Investigational Inhibitor of ATP Citrate Lyase.
|
|
Academic Article
|
Comparative effectiveness of outpatient cardiovascular disease and diabetes care delivery between advanced practice providers and physician providers in primary care: Implications for care under the Affordable Care Act.
|
|
Academic Article
|
Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial.
|
|
Academic Article
|
Lipid-Modifying Efficacy and Tolerability of Anacetrapib Added to Ongoing Statin Therapy in Patients with Hypercholesterolemia or Low High-Density Lipoprotein Cholesterol.
|
|
Academic Article
|
Adoption of the 2013 American College of Cardiology/American Heart Association Cholesterol Management Guideline in Cardiology Practices Nationwide.
|
|
Academic Article
|
Comparative effects of cholesteryl ester transfer protein inhibition, statin or ezetimibe on lipid factors: The ACCENTUATE trial.
|
|
Academic Article
|
A Multiregional, Randomized Evaluation of the Lipid-Modifying Efficacy and Tolerability of Anacetrapib Added to Ongoing Statin Therapy in Patients With Hypercholesterolemia or Low High-Density Lipoprotein Cholesterol.
|
|
Academic Article
|
Lipoprotein(a) and coronary atheroma progression rates during long-term high-intensity statin therapy: Insights from SATURN.
|
|
Academic Article
|
Efficacy and Safety of Alirocumab in High-Risk Patients With Clinical Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia (from 5 Placebo-Controlled ODYSSEY Trials).
|
|
Academic Article
|
Health disparities among adult patients with a phenotypic diagnosis of familial hypercholesterolemia in the CASCADE-FH? patient registry.
|
|
Academic Article
|
Lipid Effects of Icosapent Ethyl in Women with Diabetes Mellitus and Persistent High Triglycerides on Statin Treatment: ANCHOR Trial Subanalysis.
|
|
Academic Article
|
Statin prescription rates and their facility-level variation in patients with peripheral artery disease and ischemic cerebrovascular disease: Insights from the Department of Veterans Affairs.
|
|
Academic Article
|
Variation in Lipid-Lowering Therapy Use in Patients With Low-Density Lipoprotein Cholesterol =190 mg/dL: Insights From the National Cardiovascular Data Registry-Practice Innovation and Clinical Excellence Registry.
|
|
Academic Article
|
Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: A randomized, placebo-controlled study.
|
|
Academic Article
|
Assessment of omega-3 carboxylic acids in statin-treated patients with high levels of triglycerides and low levels of high-density lipoprotein cholesterol: Rationale and design of the STRENGTH trial.
|
|
Academic Article
|
Effect of Evolocumab on Coronary?Plaque Composition.
|
|
Academic Article
|
Effect of Infusion of High-Density Lipoprotein Mimetic Containing Recombinant Apolipoprotein A-I Milano on Coronary Disease in Patients With an Acute Coronary Syndrome in the MILANO-PILOT Trial: A Randomized Clinical Trial.
|
|
Academic Article
|
Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia.
|
|
Academic Article
|
Association of Body Mass Index With Risk Factor Optimization and Guideline-Directed Medical Therapy in US Veterans With Cardiovascular Disease.
|
|
Academic Article
|
Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol.
|
|
Academic Article
|
Effects of Icosapent Ethyl on Total?Ischemic Events: From REDUCE-IT.
|
|
Academic Article
|
ApoB, small-dense LDL-C, Lp(a), LpPLA2 activity, and cognitive change.
|
|
Academic Article
|
Poststatin Lipid Therapeutics: A Review.
|
|
Academic Article
|
Association Between Lipid Testing and Statin Adherence in the Veterans Affairs Health System.
|
|
Academic Article
|
Statin use in carnitine palmitoyltransferase II deficiency.
|
|
Academic Article
|
Effects of Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester) on Atherogenic Lipid/Lipoprotein, Apolipoprotein, and Inflammatory Parameters in Patients With Elevated High-Sensitivity C-Reactive Protein (from the ANCHOR Study).
|
|
Academic Article
|
Icosapent ethyl reduces atherogenic markers in high-risk statin-treated patients with stage 3 chronic kidney disease and high triglycerides.
|
|
Academic Article
|
Very High-Risk ASCVD and Eligibility for Nonstatin Therapies Based on the 2018?AHA/ACC Cholesterol Guidelines.
|
|
Academic Article
|
Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy.
|
|
Academic Article
|
The use of structured data elements to identify ASCVD patients with statin-associated side effects: Insights from the Department of Veterans Affairs.
|
|
Academic Article
|
REDUCE-IT USA: Results From the 3146 Patients Randomized in the United States.
|
|
Academic Article
|
Getting to an ImprOved Understanding of Low-Density Lipoprotein-Cholesterol and Dyslipidemia Management (GOULD): Methods and baseline data of a registry of high cardiovascular risk patients in the United States.
|
|
Academic Article
|
Impact of Lipid Monitoring on Treatment Intensification of Cholesterol Lowering Therapies (from the Veterans Affairs Healthcare System).
|
|
Academic Article
|
Real-world data, theoretical application of guidelines, cost, and access: how do we optimize non-statin therapy for LDL-C/non-HDL-C/ApoB?
|
|
Academic Article
|
Triglycerides and ASCVD Risk Reduction: Recent Insights and Future Directions.
|
|
Academic Article
|
Evaluation of Aspirin and Statin Therapy Use and Adherence in Patients With Premature Atherosclerotic Cardiovascular Disease.
|
|
Academic Article
|
Statin Prescription Rates, Adherence, and Associated Clinical Outcomes Among Women with PAD and ICVD.
|
|
Academic Article
|
Shared Decisions: A Qualitative Study on Clinician and Patient Perspectives on Statin Therapy and Statin-Associated Side Effects.
|
|
Academic Article
|
New Approaches for the Prevention and Treatment of Cardiovascular Disease: Focus on Lipoproteins and Inflammation.
|
|
Academic Article
|
Reduction in Revascularization With Icosapent Ethyl: Insights From REDUCE-IT Revascularization Analyses.
|
|
Academic Article
|
Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk: The STRENGTH Randomized Clinical Trial.
|
|
Academic Article
|
Transatlantic guidelines on dyslipidemia and cardiovascular risk: key differences across the pond.
|
|
Academic Article
|
Significant Facility-Level Variation in Utilization of and Adherence with Secondary Prevention Therapies Among Patients with Premature Atherosclerotic Cardiovascular Disease: Insights from the VITAL (Veterans wIth premaTure AtheroscLerosis) Registry7.
|
|
Academic Article
|
Facility-Level Variation in Reported Statin-Associated Side Effects Among Patients with Atherosclerotic Cardiovascular Disease-Perspective from the Veterans Affair Healthcare System.
|
|
Academic Article
|
Management of hyperlipidaemia among statin-intolerant patients after acute coronary syndrome: where do we stand in 2020?
|
|
Academic Article
|
Role of Bempedoic Acid in Clinical Practice.
|
|
Academic Article
|
Sex-Related Disparities in Cardiovascular Health Care Among Patients With Premature Atherosclerotic Cardiovascular Disease.
|
|
Academic Article
|
Statins and Your Memory: "Forget" About It?
|
|
Academic Article
|
Lipid Monitoring After Initiation of Lipid-Lowering Therapies: Return of Performance Measures?
|
|
Academic Article
|
2021 ACC Expert Consensus Decision Pathway on the Management of ASCVD Risk Reduction in Patients With Persistent Hypertriglyceridemia: A Report of the American College of Cardiology Solution Set Oversight Committee.
|
|
Academic Article
|
Racial Disparities in Modifiable Risk Factors and Statin Usage in Black Patients With Familial Hypercholesterolemia.
|
|
Academic Article
|
Cardiovascular Disease Risk-Based Statin Utilization and Associated Outcomes in a Primary Prevention Cohort: Insights From a Large Health Care Network.
|
|
Academic Article
|
Technology-Assisted Self-Selection of Candidates for Nonprescription Statin?Therapy.
|
|
Academic Article
|
Association of patient, provider and facility related characteristics with statin associated side effects and statin use: Insight from the Veteran's Affairs healthcare system.
|
|
Academic Article
|
Association of Low-Density Lipoprotein Testing After an Atherosclerotic Cardiovascular Event with Subsequent Statin Adherence and Intensification.
|
|
Academic Article
|
Consistency of Benefit of Icosapent Ethyl by Background Statin Type in REDUCE-IT.
|
|
Academic Article
|
Efficacy and safety of bempedoic acid in patients not receiving statins in phase 3 clinical trials.
|
|
Academic Article
|
Cost-effectiveness of Icosapent Ethyl for High-risk Patients With Hypertriglyceridemia Despite Statin Treatment.
|
|
Academic Article
|
Treatment With Icosapent Ethyl to Reduce Ischemic Events in Patients With Prior Percutaneous Coronary Intervention: Insights From REDUCE-IT PCI.
|
|
Academic Article
|
Prevention of Cardiovascular Events and Mortality With Icosapent Ethyl in Patients With Prior?Myocardial Infarction.
|
|
Academic Article
|
Guideline-Concordant Statin Therapy Use?in Secondary Prevention: Should the Medical Community Wait for Divine Intervention?
|
|
Academic Article
|
Effects of Randomized Treatment With Icosapent Ethyl and a Mineral Oil Comparator on Interleukin-1?, Interleukin-6, C-Reactive Protein, Oxidized Low-Density Lipoprotein Cholesterol, Homocysteine, Lipoprotein(a), and Lipoprotein-Associated Phospholipase A2: A REDUCE-IT Biomarker Substudy.
|
|
Academic Article
|
Lowering LDL cholesterol in clinical practice: time for change?
|
|
Academic Article
|
2022 ACC Expert Consensus Decision Pathway on the Role of Nonstatin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Solution Set Oversight Committee.
|
|
Academic Article
|
Statin Use and Risk of Diabetes by Subclinical Atherosclerosis Burden (from a Multi-Ethnic Study of Atherosclerosis Report).
|
|
Academic Article
|
A proteomic approach for investigating the pleiotropic effects of statins in the atherosclerosis risk in communities (ARIC) study.
|
|
Academic Article
|
Factors Associated With Enhanced Low-Density Lipoprotein Cholesterol Lowering With Bempedoic Acid.
|
|
Academic Article
|
Use of optimal medical therapy in patients with diabetes and atherosclerotic cardiovascular disease: Insights from a prospective longitudinal cohort study.
|
|
Academic Article
|
Phase 2b Randomized Trial of the Oral PCSK9 Inhibitor MK-0616.
|
|
Academic Article
|
Cluster Randomized Trial of a Personalized Clinical Decision Support Intervention to Improve Statin Prescribing in Patients With Atherosclerotic Cardiovascular Disease.
|
|
Academic Article
|
The importance of low-density lipoprotein cholesterol measurement and control as performance measures: A joint Clinical Perspective from the National Lipid Association and the American Society for Preventive Cardiology.
|
|
Academic Article
|
Intensity of Lipid-Lowering Therapy Among Patients With Polyvascular Disease.
|
|
Academic Article
|
Lipid-Lowering Therapy in the Elderly: Are Current Guidelines a Sign of Ageism in Medical Care?
|
|
Academic Article
|
Obicetrapib plus ezetimibe as an adjunct to high-intensity statin therapy: A randomized phase 2 trial.
|
|
Academic Article
|
Efficacy and safety of bempedoic acid in patients with and without metabolic syndrome: Pooled analysis of data from four phase 3 clinical trials.
|
|
Academic Article
|
The 2022 American College of Cardiology Expert Consensus on the Role of Nonstatin Therapies: An Expert-Guided Tour.
|
|
Academic Article
|
Icosapent ethyl following acute coronary syndrome: the REDUCE-IT trial.
|